Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
RenovoRx Inc
RNXT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.11
0.07
6.73%
Ult. Agg.: Nov 18, 12:20 PM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
RenovoRx Financials
RenovoRx (RNXT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CORRECTION: RenovoRx Q3 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
PRO
RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.
Benzinga Newsdesk
PRO
RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est
RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.
Benzinga Newsdesk
PRO
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same
Benzinga Newsdesk
PRO
RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
Benzinga Newsdesk
PRO
RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The
Benzinga Newsdesk